Please login to the form below

Not currently logged in
Email:
Password:

INC Research/InVentiv Health becomes Syneos Health

Renamed company will focus on biopharmaceutical solutions

Syneos HealthContract research organisation INC Research and commercial services group InVentiv Health have rebranded as Syneos Health following their merger early last year.

The newly-renamed biopharmaceutical services provider comprises of more than 21,000 employees in clinical and commercial development combining contract research organisation and contract commercial organisation capabilities.

More specifically, the company - which becomes the second largest outsourcing provider after IQVIA - combines behavioural insights to accelerate clinical trial recruitment and therapeutic know-how with multi-channel commercial programs to engage stakeholders.

Alistar Macdonald, chief executive officer of Syneos Health, said: “Syneos Health fully expresses our value proposition – that is our capability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialise their therapies.

“Unlike traditional CROs and commercialisation businesses, we are knocking down walls and enabling clinical and commercial experts to work in sync by using the latest technologies, advanced business practices and the advantages of scale.

“Our biopharmaceutical acceleration model is unique to the industry, and from this ambitious vision, Syneos Health was born.”

The company said ‘Syneos’ communicates the value of synchronising clinical and commercial capabilities to accelerate customer performance.

Macdonald added: “As commercialisation experts, we understand the importance a strong brand plays in creating differentiation, conversion and loyalty.

“Our new identity reinforces our fully integrated business model, positions Syneos Health as a high-value solutions partner, and is designed to attract and retain top talent committed to shortening the distance from lab to life.”

Article by
Gemma Jones

5th January 2018

From: Research, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics